Holen Sie sich die Stockscreener-App
2.0603
3.70%
-0.0997
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.16
Offen:
$2.21
24-Stunden-Volumen:
1.25M
Relative Volume:
0.48
Marktkapitalisierung:
$915.04M
Einnahmen:
$49.80M
Nettoeinkommen (Verlust:
$-50.34M
KGV:
-14.84
EPS:
-0.1388
Netto-Cashflow:
$-67.85M
1W Leistung:
-2.34%
1M Leistung:
+23.82%
6M Leistung:
+45.46%
1J Leistung:
+215.21%
1-Tages-Spanne:
$2.06
$2.2195
1-Wochen-Bereich:
$2.07
$2.29
52-Wochen-Spanne:
$0.615
$2.53
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
2.06 | 959.46M | 49.80M | -50.34M | -67.85M | -0.1388 |
VRTX
Vertex Pharmaceuticals Inc
|
436.11 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
641.73 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.68 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.75 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.51 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX) - Insider Monkey
LXRX Stock Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
LXRX Stock Price, Quote & Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
Lexicon anticipates SONATA-HCM enrollment completion by mid-2026 while highlighting $100m Hercules debt facility - MSN
A Look At Lexicon Pharmaceuticals (LXRX) Valuation After Improved Q1 Revenue And Narrowed Net Loss - Sahm
Lexicon Pharmaceuticals: up to 50 percent of type 2 diabetes patients affected by painful neuropathy - Traders Union
Lexicon Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-05-15 - Seeking Alpha
Navigating Life with Hypertrophic Cardiomyopathy - GlobeNewswire Inc.
Lexicon Pharmaceuticals (LXRX) Is Up 52.5% After Q1 Loss Narrows And Revenue JumpsHas The Bull Case Changed? - simplywall.st
Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's Changed - Yahoo Finance
Lexicon Pharmaceuticals management to join Nasdaq HQ fireside chat - Traders Union
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - Herald and News
LXRX Maintained by Citigroup -- Price Target Raised to $3.10 - GuruFocus
$Lexicon Pharmaceuticals (LXRX.US)$ 🚀🚀🚀🚀🚀🤩🤩🤩🤩🤩 - Moomoo
Citigroup Issues Positive Forecast for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price - MarketBeat
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $3.1 - Moomoo
Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones - Yahoo Finance
Lexicon Pharmaceuticals (LXRX) reports break-even earnings for Q1 - MSN
[SCHEDULE 13D/A] LEXICON PHARMACEUTICALS, INC. Amended Major Shareholder Report - Stock Titan
Major holder Artal group converts LXRX (LXRX) Series B preferred into 20.4M common shares - Stock Titan
5 Best Fast Growing Penny Stocks to Buy Right Now - Insider Monkey
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
LXRX SEC FilingsLexicon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Q1 2026 Lexicon Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Lexicon Pharmaceuticals: Buy Rating Reiterated as Value Catalysts Build; $6 Price Target Maintained - TipRanks
Lexicon Pharmaceuticals Q1 2026 earnings preview - MSN
Lexicon: Q1 Earnings Snapshot - theheraldreview.com
Lexicon Pharmaceuticals Q1 Earnings Call Highlights - Barchart.com
Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
LXRX Financials: Income Statement, Balance Sheet & Cash Flow | Lexicon Pharmaceuticals Inc - Stock Titan
Lexicon Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Lexicon Pharmaceuticals (NASDAQ: LXRX) Q1 2026 loss narrows on Novo milestones - Stock Titan
Earnings call transcript: Lexicon Pharmaceuticals Q1 2026 sees dramatic revenue surge - Investing.com Nigeria
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1 - Yahoo Finance
LEXICON PHARMACEUTICALS ($LXRX) Releases Q1 2026 Earnings - Quiver Quantitative
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates - The Manila Times
Lexicon targets diabetes filing, heart trial, obesity study milestones - Stock Titan
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lexicon (NASDAQ: LXRX) Q1 2026 results, milestones and $100M loan - Stock Titan
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DEBBANE RAYMOND | Director |
Feb 25 '26 |
Buy |
1.49 |
2,000 |
2,980 |
1,906,186 |
| DEBBANE RAYMOND | Director |
Feb 23 '26 |
Buy |
1.47 |
100,000 |
147,000 |
1,904,186 |
| DEBBANE RAYMOND | Director |
Feb 20 '26 |
Buy |
1.48 |
100,000 |
147,790 |
1,804,186 |
| DEBBANE RAYMOND | Director |
Feb 19 '26 |
Buy |
1.44 |
50,000 |
71,965 |
1,704,186 |
| DEBBANE RAYMOND | Director |
Feb 18 '26 |
Buy |
1.32 |
133,688 |
176,468 |
1,654,186 |
| DEBBANE RAYMOND | Director |
Feb 17 '26 |
Buy |
1.31 |
76,857 |
100,544 |
1,520,498 |
| DEBBANE RAYMOND | Director |
Feb 13 '26 |
Buy |
1.31 |
57,952 |
75,877 |
1,443,641 |
| Invus Global Management, LLC | Director |
Feb 02 '26 |
Buy |
1.30 |
1,538,462 |
2,000,001 |
1,538,462 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):